Home › Funds › Kynam Capital Management, LP › PHVS
Kynam Capital Management, LP position in PHVS
PHARVARIS N V · Health Care
Kynam Capital Management, LP reported holding 661,795 shares of PHVS (PHARVARIS N V) in its Q2 2026 13F filing — a position valued at US$22.9M, representing 1.26% of its reported portfolio and ranking #19 among its reported holdings. Kynam Capital Management, LP has disclosed PHVS holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Kynam Capital Management, LP's PHVS position evolved
Kynam Capital Management, LP first disclosed a stake in PHVS in Q3 2025 at 675,000 shares (US$16.8M). The position peaked in Q2 2026 at 661,795 shares, worth US$22.9M. Across 4 filings, Kynam Capital Management, LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 661,795 shares valued at US$22.9M — an increase of 21,400 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 675.00K | $16.84M | New |
| Q4 2025 | 640.39K | $17.77M | Reduce |
| Q1 2026 | 640.39K | $18.09M | Hold |
| Q2 2026 | 661.79K | $22.88M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHVS and 13F data
PHVS (PHARVARIS N V) is a Health Care company. 49 other funds we track also report a position in PHVS — the largest reported positions include GENERAL ATLANTIC, L.P. (US$226.5M), Foresite Capital Management IV, LLC (US$165.2M), venBio Partners LLC (US$160.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHVS
- GENERAL ATLANTIC, L.P. 6.55M sh · $226.53M · Q2 2026
- Foresite Capital Management IV, LLC 4.78M sh · $165.24M · Q2 2026
- venBio Partners LLC 4.64M sh · $160.57M · Q2 2026
- EQT Fund Management S.a r.l. 3.42M sh · $118.42M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.38M sh · $116.74M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 2.68M sh · $92.52M · Q2 2026
- Commodore Capital LP 1.43M sh · $49.28M · Q2 2026
- Novo Holdings A/S 1.40M sh · $48.41M · Q2 2026
- Saturn V Capital Management LP 1.31M sh · $45.44M · Q2 2026
- TCG Crossover Management, LLC 1.01M sh · $34.86M · Q2 2026
- Sofinnova Investments, Inc. 881.30K sh · $30.48M · Q2 2026
- 5AM Venture Management, LLC 797.60K sh · $27.58M · Q2 2026
More on Kynam Capital Management, LP
FAQ
How long has Kynam Capital Management, LP held PHVS?
Kynam Capital Management, LP has disclosed PHVS holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Kynam Capital Management, LP's current position in PHVS?
As of Q2 2026, Kynam Capital Management, LP holds 661.79K shares of PHVS (PHARVARIS N V), valued at $22.88M, representing 1.26% of its reported portfolio and ranking #19.
Has Kynam Capital Management, LP been buying or selling PHVS?
In the latest 13F filing (Q2 2026), Kynam Capital Management, LP increased its position in PHVS. The position peaked in Q2 2026 at 661.79K shares.
Which other funds hold PHVS?
Other major institutional holders of PHVS include GENERAL ATLANTIC, L.P., Foresite Capital Management IV, LLC, venBio Partners LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.